

Ana Ruiz Casado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6067191/publications.pdf>

Version: 2024-02-01

52
papers

1,337
citations

566801

15
h-index

344852

36
g-index

53
all docs

53
docs citations

53
times ranked

2133
citing authors

#	ARTICLE	IF	CITATIONS
1	Tratamiento de las metástasis hepáticas de cáncer colorrectal con y-90: el problema es la toxicidad. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 67-68.	0.0	0
2	Treatment of colorectal liver metastases with y-90: the problem is the toxicity. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 67-68.	0.1	0
3	Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial. British Journal of Cancer, 2022, 126, 874-880.	2.9	3
4	Cancer-related Fatigue in Breast Cancer Survivors: A Review. Clinical Breast Cancer, 2021, 21, 10-25.	1.1	74
5	Clinical outcomes of FOLFIRINOX and gemcitabine+nab paclitaxel for metastatic pancreatic cancer in the real world setting. Clinical and Translational Oncology, 2021, 23, 812-819.	1.2	11
6	Prevalence and correlates of cancer-related fatigue in breast cancer survivors. Supportive Care in Cancer, 2021, 29, 6523-6534.	1.0	15
7	Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers, 2021, 13, 4514.	1.7	6
8	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. Journal of Clinical Medicine, 2020, 9, 3889.	1.0	35
9	474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC). Annals of Oncology, 2020, 31, S442-S443.	0.6	1
10	A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective. ESMO Open, 2020, 5, e000850.	2.0	2
11	Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. Cancers, 2020, 12, 2259.	1.7	6
12	1873P Cancer-related fatigue: Are we evaluating it?. Annals of Oncology, 2020, 31, S1067-S1068.	0.6	0
13	471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score. Annals of Oncology, 2020, 31, S441.	0.6	0
14	Some unanswered questions about older adults with metastatic pancreatic cancer. Journal of Geriatric Oncology, 2020, 11, 1032-1033.	0.5	1
15	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. Cancers, 2020, 12, 657.	1.7	14
16	Concurrent Exercise Interventions in Breast Cancer Survivors with Cancer-related Fatigue. International Journal of Sports Medicine, 2020, 41, 790-797.	0.8	14
17	Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. International Journal of Colorectal Disease, 2020, 35, 739-746.	1.0	12
18	POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers. Annals of Oncology, 2019, 30, v221.	0.6	0

#	ARTICLE	IF	CITATIONS
19	EUropean REcommendations for female FERtility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 233-240.	2.0	47
20	Enteritis inducida por quimioterapia: experiencia institucional y revisión bibliográfica. <i>Revista Clínica Española</i> , 2019, 219, 165-167.	0.2	1
21	Noncirrhotic portal hypertension: An under-reported late adverse event of SIRT in metastatic colorectal cancer patients. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 42.	0.3	9
22	Exercise prehabilitation program for patients under neoadjuvant treatment for rectal cancer: A pilot study. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 20.	0.3	25
23	RAS analysis of circulating tumor cells from advanced colorectal cancer using BEAMing technology.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15151-e15151.	0.8	0
24	Cardiorespiratory fitness and adiposity in breast cancer survivors: is meeting current physical activity recommendations really enough?. <i>Supportive Care in Cancer</i> , 2018, 26, 2293-2301.	1.0	7
25	Physical activity levels are low in patients with pulmonary hypertension. <i>Annals of Translational Medicine</i> , 2018, 6, 205-205.	0.7	19
26	Lengua geográfica inducida por inhibidores de la angiogénesis. <i>Revista Clínica Española</i> , 2018, 218, 501-502.	0.2	2
27	Geographic tongue induced by angiogenesis inhibitors. <i>Revista Clínica Española</i> , 2018, 218, 501-502.	0.3	0
28	First-line treatment with panitumumab plus FOLFIRI in elderly patients with <i>RAS/BRAF</i> wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3618-TPS3618.	0.8	2
29	Threats for sustainability of multidisciplinary working. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1291-1297.	0.3	1
30	Cardio-respiratory fitness and functional performance in patients with a recent diagnosis of colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 804-804.	0.8	0
31	Exercise and the Hallmarks of Cancer. <i>Trends in Cancer</i> , 2017, 3, 423-441.	3.8	124
32	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , 2017, 18, 1159-1171.	5.1	293
33	Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report. <i>Annals of the Royal College of Surgeons of England</i> , 2017, 99, e225-e226.	0.3	3
34	Cancer-related fatigue in cancer survivors (CS) with no active treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 238-238.	0.8	0
35	Cancer-related fatigue in breast cancer survivors: more evidence for a physiological substrate. <i>Annals of Oncology</i> , 2016, 27, vi518.	0.6	0
36	Validity of the Physical Activity Questionnaires IPAQ-SF and GPAQ for Cancer Survivors: Insights from a Spanish Cohort. <i>International Journal of Sports Medicine</i> , 2016, 37, 979-985.	0.8	31

#	ARTICLE	IF	CITATIONS
37	Regular physical activity: a little is good, but is it good enough?. American Journal of Clinical Nutrition, 2015, 101, 1099-1101.	2.2	4
38	Physical Inactivity and Low Fitness Deserve More Attention to Alter Cancer Risk and Prognosis. Cancer Prevention Research, 2015, 8, 105-110.	0.7	67
39	Erysipeloid rash: A rare adverse event induced by gemcitabine. Journal of Cancer Research and Therapeutics, 2015, 11, 1024.	0.3	3
40	Objectively Assessed Physical Activity Levels in Spanish Cancer Survivors. Oncology Nursing Forum, 2014, 41, E12-E20.	0.5	16
41	Clinical audit of multidisciplinary care at a medium-sized hospital in Spain. World Journal of Surgical Oncology, 2014, 12, 53.	0.8	5
42	Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Annals of Oncology, 2013, 24, 2342-2349.	0.6	89
43	Interstitial Granulomatous Drug Reaction to Sorafenib. Archives of Dermatology, 2011, 147, 1119.	1.7	19
44	An autopsy case of acute pulmonary toxicity related to irinotecan. Clinical and Translational Oncology, 2008, 10, 597-598.	1.2	2
45	Superficial Thrombophlebitis As An Exceptional Complication Of A Scrotal Arteriovenous Malformation. Clinical and Translational Oncology, 2007, 9, 59-59.	1.2	0
46	Pulmonary toxicity of 5-fluoracil and oxaliplatin. Clinical and Translational Oncology, 2006, 8, 624-624.	1.2	15
47	Life-threatening adverse drug reaction to paclitaxel. Postmarketing surveillance. Clinical and Translational Oncology, 2006, 8, 60-61.	1.2	3
48	Liver metastases of colon cancer: New therapeutic approaches. Neoadjuvant chemotherapy. Oncologia, 2006, 29, .	0.0	0
49	Progress in the clinical development of new marine-derived anticancer compounds. Anti-Cancer Drugs, 2004, 15, 321-329.	0.7	79
50	Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer, 2003, 98, 832-840.	2.0	97
51	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. Journal of Clinical Oncology, 2003, 21, 3207-3213.	0.8	177
52	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. Bone Marrow Transplantation, 2001, 27, 117-123.	1.3	3